Compositions and methods for treating immunological dysfunction

Abstract

The present invention is directed to methods of lymphotherapy to treat cancer, infection and autoimmune disease.

1 . A ghost cell trainer (GHT), wherein said GHT comprises a plasma membrane having:
 a. a plurality of MEW molecules; and   b. a plurality of a protein of interest, wherein the protein is glycosylphosphatidylinositol (GPI) anchored on the cell surface.   
     
     
         2 . A method of treating a subject having cancer, the method comprising:
 a. transfecting a cell expressing a major histocompatibility complex (MHC) molecule with a plurality of vectors each comprising a gene encoding a protein of interest and a glycosylphosphatidylinositol (GPI) signaling anchor, or a vector comprising a fusion gene encoding a plurality of proteins of interest and GPI signaling anchors, such that the proteins of interest are expressed and anchored to the cell surface via the GPI signaling anchors, wherein the proteins of interest include IL-15, IL-21, IL-2, CD86, CD64, and CD137L;   b. lysing the cell of step (a) by hypotonic means to form a ghost cell (GHC) that is substantially free of all intracellular components;   c. co-culturing the GHC with an immune cell isolated from the subject to expand and activate the immune cell, wherein the immune cell is a B cell; and   d. infusing the activated immune cell into the subject.   
     
     
         3 . The method of  claim 2 , wherein the GPI anchored proteins of interest are within a lipid raft. 
     
     
         4 . The method of  claim 2 , wherein the MEW molecule is HLA-Cw*3 and/or HLA-Cw*5. 
     
     
         5 . The method of  claim 2 , wherein said GHC is of human, canine, feline, murine, or equine origin. 
     
     
         6 . The method of  claim 2 , wherein said GHC is derived from a primary cell culture or an immortalized cell line. 
     
     
         7 . The method of  claim 6 , wherein the immortalized cell line is K562 or Jurkat. 
     
     
         8 . The method of  claim 2 , wherein the cancer is a hematologic cancer or a solid cancer. 
     
     
         9 . The method of  claim 8 , wherein the hematologic cancer is leukemia or lymphoma. 
     
     
         10 . The method of  claim 8 , wherein the solid cancer is osteosarcoma, hemangiosarcoma, transitional cell carcinoma, melanoma, glioblastoma, neuroblastoma, mammary carcinoma, or a sarcoma or carcinoma of the gastrointestinal system. 
     
     
         11 . The method of  claim 2 , wherein the subject is a canine, feline, or equine. 
     
     
         12 . A method of treating a subject having cancer, the method comprising:
 a. transfecting a cell with
 i. a vector encoding a major histocompatibility complex (MHC) molecule and a glycosylphosphatidylinositol (GPI) signaling anchor; and 
 ii. a plurality of vectors each comprising a gene encoding a protein of interest and a GPI signaling anchor, or a vector comprising a fusion gene encoding a plurality of proteins of interest and GPI signaling anchors, such that the MHC molecule and the proteins of interest are expressed and anchored to the cell surface via the GPI signaling anchors, wherein the proteins of interest include IL-15, IL-21, IL-2, CD86, CD64, and CD137L; 
   b. lysing the cell of step (a) by hypotonic means to form a ghost cell (GHC) that is substantially free of all intracellular components;   c. co-culturing the GHC with an immune cell isolated from the subject to expand and activate the immune cell, wherein the immune cell is a B cell; and   d. infusing the activated immune cell into the subject.   
     
     
         13 . The method of  claim 12 , wherein said GHC is of human, canine, feline, murine, or equine origin. 
     
     
         14 . The method of  claim 12 , wherein the proteins of interest are within a lipid raft. 
     
     
         15 . The method of  claim 12 , wherein the WIC molecules are GPI anchored on the cell surface within a lipid raft. 
     
     
         16 . The method of  claim 12 , wherein the WIC molecules are HLA-Cw*3 and/or HLA-Cw*5. 
     
     
         17 . The method of  claim 12 , wherein said GHC is derived from a primary cell culture or an immortalized cell line. 
     
     
         18 . The method of  claim 17 , wherein the immortalized cell line is K562 or Jurkat. 
     
     
         19 . The method of  claim 12 , wherein the cancer is leukemia, lymphoma, osteosarcoma, hemangiosarcoma, transitional cell carcinoma, melanoma, glioblastoma, neuroblastoma, mammary carcinoma, or a sarcoma or carcinoma of the gastrointestinal system. 
     
     
         20 . The method of  claim 12 , wherein the subject is a canine, feline, or equine.